Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 17; no. 3; pp. 186 - 191
• Main Authors: Franco, F, Lavernia, J, Aguiar-Bujanda, D, Miramón, J, Gumá, J, Álvarez, R, Gómez-Codina, J, García Arroyo, F, Llanos, M, Marin Vera, M, Alfaro, J, Quero, C, Delgado, M, Nogales, E, Menarguez, F, Martinez, M, Torrente, M, Royuela, M, Abreu, D, Provencio, M
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-03-2017
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Breast Neoplasms, Male - drug therapy; Breast Neoplasms, Male - mortality; Breast Neoplasms, Male - pathology; Chemotherapy; Disease-Free Survival; Extranodal lymphoma; Female; Hematology, Oncology and Palliative Medicine; Humans; Immunotherapy; Lumpectomy; Lymph Nodes - pathology; Lymphoma - drug therapy; Lymphoma - mortality; Lymphoma - pathology; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - mortality; Male; Middle Aged; Neoplasms of the breast; Prognosis; Treatment Outcome; Extranodal lymphoma; Lumpectomy; Chemotherapy; Neoplasms of the breast; Immunotherapy
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/j.clml.2016.09.004

Abstract Primary breast lymphoma is a rare form of localized extranodal lymphoma, which affects the mammary glands unilaterally or bilaterally, and can also affect the regional lymph nodes. Materials and methods We reviewed 55 patients, stages IE and IIE, diagnosed in 16 Spanish institutions between 1989 and 2016. A serial of clinical variables and treatment were collected, and overall survival (OS) and progression-free survival (PFS) were calculated. Results Out of the 55 patients, 96,4% were women with an average age of 69 years. A total of 53 patients correspond to non-Hodgkin lymphoma (NHL), of whom 36,3% had lymph node involvement upon diagnosis. 58,2% were stage IE and 41.8% stage IIE. Treatments received included radiotherapy (36,3%), chemotherapy (85,5%) and rituximab (in 38 of the 45 patients with NHL treated with chemotherapy). In all, 82,2% of complete responses was achieved. OS and PFS at 5 years in NHL patients was 76% and 73%, respectively. Conclusion Current treatments (chemotherapy, immunotherapy and radiotherapy) achieve good control of the disease, with an OS of 5 years in 80% of the patients, although there is no consensus in treatment, given the scarce incidence of these lymphomas.